ArticleBiochemistry research international2026
Noncatalytic Functions Are Required for MPO and PON1 in Modulating the Involvement of Monocytes and Endothelial Cells in Atherosclerosis.
Article in Biochemistry research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Noncatalytic Functions Are Required for MPO and PON1 in Modulating the Involvement of Monocytes and Endothelial Cells in Atherosclerosis.Biochemistry research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-density lipoproteins (HDLs) are deeply implicated in atherosclerosis. HDL, myeloperoxidase (MPO), and paraoxonase-1 (PON1) form a functional ternary complex where PON1 partially inhibits the MPO activity, and MPO in turn partially inactivates PON1. The activity of MPO is dependent on the concentration of hydrogen peroxide, but the extremely low concentrations of hydrogen peroxide in serums severely constrain MPO activity. PON1 has the activities of organophosphatase, arylesterase, and thiolactonase, but these hydrolase activities are extraneous to antioxidative stress. Thus, we proposed that MPO and PON1 may be involved in atherosclerosis by acting as proteins, rather than enzyme activities. Cholesterol efflux assay, ATP-binding cassette transporter A1 (ABCA1)-dependent cholesterol efflux, and LCAT activity assay were performed. The effect of MPO, PON1, and serums from the individuals with ASCVD and healthy individuals on cholesterol efflux of human acute monocytic leukemia cell line (THP-1 cells) was compared. Noncatalytic functions of MPO and PON1 were analyzed using recombinant proteins and neutralizing antibodies. Wound healing assay and tube formation assay were used to analyze noncatalytic functions of MPO and PON1 in modulating the involvement of human umbilical vein endothelial cells (HUVECs). We found that MPO protein decreased the cholesterol efflux; by contrast, PON1 protein increased the cholesterol efflux of THP-1 cells. Importantly, MPO antibody partially restored cholesterol efflux, but PON1 antibody partially reduced cholesterol efflux of THP-1 cells. Moreover, ABCA1 was necessary for controlling the involvement of MPO and PON1 in modulating cholesterol efflux of THP-1 cells. There existed the confrontations between the noncatalytic functions of PON1 and MPO in migration of endothelial cells. Instead, MPO protein enhanced the expression of intercellular adhesion molecule-1 (ICAM-1) and E-selectin of HUVECs; nonetheless, PON1 protein reduced the expression of these adhesion molecules. Of note, PON1 protein was unable to balance out the induction of MPO protein for these adhesion molecules in that the expression of these adhesion molecules generated by the combination of MPO protein and PON1 protein was similar to that of MPO. The activation of THP-1 cells induced by MPO protein directly impaired in vitro microvascular structure via increasing the expression of IL-6 and TNFα regulated by NF-κB p65 of THP-1 cells. Together, the noncatalytic functions entail MPO and PON in modulating the involvement of monocytes and endothelial cells in atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.